Navigation Links
GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

om.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2005.


    Notes to editors:

TYKERB(R) is a registered trademark of the GlaxoSmithKline group of companies

in the United States. To access the latest GSK Oncology media materials, visit

http://www.gsk.com


    Enquiries:

    On-site at ASCO                       Robin Fastenau 1 919 522 5237

    US Media enquiries:                   Mary Anne Rhyne 1 919 483 2839


    UK Media enquiries:                   Philip Thomson 44 20 8047 5502

                                          Alice Hunt 44 20 8047 5502

                                          Gwenan White 44 20 8047 5502


    European Analyst/Investor enquiries:  Anita Kidgell 44 20 8047 5542

                                          Sally Ferguson 44 20 8047 5543

                                          David Mawdsley 44 20 8047 5564


    US Analyst/ Investor enquiries:       Frank Murdolo 1 215 751 7002

                                          Tom Curry 1 215 751 5419


    References:

    (1)  Sonpavde, G. and Hutson, T. Pazopanib: A Novel Multitargeted Tyrosine

         Kinase Inhibitor. Curr Oncol Rep. 2007; Mar;9(2):115-9

    (2)  Jain RK. Antiangiogenic therapy for cancer: current and emerging

         concepts. Oncology. 2005 Apr;19(4 Suppl 3):7-16

    (3)  Hutson, T. E., Davis I. D., et al. Pazopanib (GW786034) is active 
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:1/23/2015)... Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), ... extracorporeal cytokine adsorber to reduce deadly inflammation in ... of $385,642, net of transaction costs, in non-dilutive ... Business Tax Certificate Transfer Program sponsored by the ...
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... Over 200 organizations, community leaders, health care professionals, ... across the country today urged Express Scripts to ... and allow the nation,s largest pharmacy chain to return ... stopped providing in-network coverage for prescriptions filled at Walgreens ...
... SUNNYVALE, Calif., Jan. 17, 2012   Accuray Incorporated ... company, announced today that CHRISTUS MUGUERZA Hospital Alta Especialidad ... CyberKnife® Robotic Radiosurgery System . CHRISTUS MUGUERZA is ... benefits of the CyberKnife System to treat tumors anywhere ...
Cached Medicine Technology:Over 200 Community Leaders and Organizations Across the Nation Urge Express Scripts To Reach Agreement With Walgreens 2First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 2First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 3First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 4
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... Richmond, VA (PRWEB) January 22, 2015 ... the power at the Science Museum of Virginia. Wicked ... 24. , Wicked Plants unearths 75 poisonous, carnivorous and ... traverse through each room to uncover the biochemical, physical ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... The New Year is here, but are ... pounds in a healthy way that,ll,last past ... GlaxoSmithKline at:, http://media.medialink.com/WebNR.aspx?story=34274 , Registered journalists ... for free and unrestricted use at ...
... Biosciences,Inc. (Nasdaq: RDEA ) today announced that ... the United Kingdom has authorized a,Phase 2a clinical ... (NNRTI), in patients with human immunodeficiency,virus (HIV), the ... clear unmet need for new NNRTIs that have ...
... The board of trustees of,the Pan American Health ... executive director. He comes to the foundation with 30 ... He,follows Ms. Jess Gersky who is retiring at the ... served as the mission director in Mexico for,the US ...
... Cancer Center in Philadelphia have found that a signaling ... is turned on in nearly all recurrent prostate cancers ... hold up, the protein, called Stat5, may be a ... In addition, the researchers, led by Marja Nevalainen, M.D., ...
... happen to kids if precautions are skipped, experts say ... provide kids with great exercise and fun, but proper ... trauma experts. , "We see a startling number of ... and beyond," Amy Teddy, manager of the pediatric injury ...
... 28 Grubb & Ellis,Healthcare REIT, Inc. has acquired ... on December 21, 2007., Park Place Office Park ... square feet on eight and a half,acres in Dayton, ... in 1987,1988, and 2002, respectively, and offer tenants a ...
Cached Medicine News:Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 2Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 3Health News:International Development Expert to Lead the Pan American Health and Education Foundation 2Health News:Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer 2Health News:Put Safety First During Winter Fun 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 3
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
Soft Guedel Oral Airways...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... Rapid intubation of difficult airways., ... time and accuracy are critical. Now you ... effective ventilation with the Combitube®: Esophageal/Tracheal double-Lumen ... the Combitube airway is designed to establish ...
Medicine Products: